Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
Healthy Volunteers
NCT05966649

Synbiotics in Patients at RIsk fOr Preterm Birth

Led by Ziekenhuis Oost-Limburg · Updated on 2026-02-27

402

Participants Needed

9

Research Sites

324 weeks

Total Duration

On this page

Sponsors

Z

Ziekenhuis Oost-Limburg

Lead Sponsor

F

Federaal Kenniscentrum voor Gezondheidszorg, Belgium

Collaborating Sponsor

AI-Summary

What this Trial Is About

Prematurity remains the main cause of death and serious health problems in new-borns. Besides the need for hospitalization and medical interventions in the first weeks or months of the new-borns' life, prematurity can cause long-lasting health problems (e.g. multiple hospital admissions, developmental delay, learning difficulties, motor delay, hearing or eye problems, ...). Moreover, prematurity places an enormous economic burden on the society. Aside from the medical problems and the financial cost, the emotional stress and psychological impact on the parents, siblings and other family members should not be underestimated. Previous preterm delivery (before 37 weeks of pregnancy) increases the risk for recurrent preterm delivery in a subsequent pregnancy. Therefore, these women should be considered as 'high risk' for preterm birth. Infections ascending from the vagina may be an important cause of preterm delivery in certain cases. Some women have an abnormal vaginal microbiome and are therefore at risk for infections and preterm birth. On the other hand, the vaginal flora is more stable and resistant to infections in healthy pregnant women who deliver at term (after 37 weeks of gestation). Synbiotics are a mixture containing probiotics and prebiotics. Probiotics are living bacteria with potential beneficial effects that can be used safely in pregnancy, while prebiotics are consumed by the bacteria. It is known that probiotics, when used for a long period of time, can maintain a healthy and stable vaginal flora that may protect against infections. In this study, pregnant patients with a history of preterm birth will be included in the first trimester of pregnancy to start with synbiotics or placebo. The investigators will examine the effect of synbiotics on the vaginal flora and on the pregnancy duration. The hypothesis is that synbiotics, when started early in the pregnancy, can change the disturbed vaginal flora into a stable micro-environment.

CONDITIONS

Official Title

Synbiotics in Patients at RIsk fOr Preterm Birth

Who Can Participate

Age: 18Years +
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed written informed consent before any study assessments
  • 18 years of age or older
  • Singleton pregnancy
  • Pregnancy consultation between 8 and 10 weeks gestation
  • At least one of the following risk factors for spontaneous preterm birth: prior spontaneous preterm birth between 24 and 36 weeks, preterm premature rupture of membranes (PPROM) before 36 weeks in a previous pregnancy, or prior spontaneous second-trimester pregnancy loss between 14 and 24 weeks
Not Eligible

You will not qualify if you...

  • Currently using pro-, pre-, or synbiotics and unwilling to stop
  • Multiple pregnancy
  • Need for primary (type 1) cerclage
  • Inflammatory bowel disease
  • Known congenital uterine anomaly
  • History of LLETZ conization

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 9 locations

1

Universitaire Ziekenhuis Antwerpen

Edegem, Antwerpen, Belgium, 2650

Actively Recruiting

2

Ziekenhuis Oost-Limburg

Genk, Limburg, Belgium, 3600

Actively Recruiting

3

Universitaire Ziekenhuizen Leuven

Leuven, Limburg, Belgium, 3000

Actively Recruiting

4

CHR Citadelle

Liège, Liège, Belgium, 4000

Actively Recruiting

5

UZ Gent

Ghent, Oost-Vlaanderen, Belgium, 9000

Actively Recruiting

6

AZ Sint-Jan

Bruges, West-Vlaanderen, Belgium, 8300

Actively Recruiting

7

AZ Sint-Lucas

Bruges, West-Vlaanderen, Belgium, 8310

Actively Recruiting

8

AZ Maria Middelares

Ghent, West-Vlaanderen, Belgium, 9000

Actively Recruiting

9

AZ Groeninge

Kortrijk, Belgium, 8500

Actively Recruiting

Loading map...

Research Team

C

Caroline Van Holsbeke, PhD

CONTACT

K

Katrien Nulens, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here